Development of specific peptide reagents for serologic monitoring of Exostosin autoantibodies in membranous lupus nephritis
膜性狼疮肾炎外骨蛋白自身抗体血清学监测特异性肽试剂的开发
基本信息
- 批准号:10545924
- 负责人:
- 金额:$ 25.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-05 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:AddressAffinityAntibodiesAntigen-Antibody ComplexAntigensAutoantibodiesAutoantigensAutoimmuneBacteriophage M13BacteriophagesBindingBiocompatible MaterialsBioinformaticsBiological AssayBiopsyBiopsy SpecimenCellsClinicClinicalDepositionDevelopmentDiagnosisDiagnosticDiagnostic ReagentDiagnostic testsDialysis procedureEXT1 geneEnzyme-Linked Immunosorbent AssayEtiologyExhibitsFreezingFutureG-substrateHealthcare SystemsImmobilizationImmunoglobulin GIncidenceIncubatedIndividualInjuryKidney FailureLaboratoriesLibrariesLupus NephritisMass Spectrum AnalysisMembraneMembranous GlomerulonephritisMethodsMolecularMonitorMovementNephrologyNephrotic SyndromePatient CarePatientsPatternPeptidesPhage DisplayPhasePhospholipase A2PopulationProteinsProteomicsProviderPublishingReagentRecombinant ProteinsRecombinantsReportingResearchRiskSamplingSensitivity and SpecificitySequence AnalysisSerologySerology testSerumSignal TransductionSpecificityStainsSubgroupSurveysSystemic Lupus ErythematosusTestingThrombospondinsTissuesTransplantationTransplantation Surgerybasebiobankbioinformatics pipelineexperiencekidney biopsylaser capture microdissectionnext generation sequencingnovelphase 2 testingprecision medicineprogramsprotein aminoacid sequencereceptorscreeningsuccesssynthetic peptidetreatment response
项目摘要
Project Summary
Up to half of patients with systemic lupus erythematosus (SLE) will develop lupus nephritis (LN), and
nearly a third of LN patients will develop kidney failure requiring dialysis or transplantation. One type of LN,
membranous lupus nephritis (MLN) exhibits similar clinical hallmarks and patterns of injury as compared to non-
lupus associated membranous nephropathy (MN). MN and MLN are largely diagnosed through histopathological
analysis of kidney biopsies. Moreover, autoantigens have been identified in MN, with M-type phospholipase A2
receptor (PLA2R) autoantibodies present in nearly 70% of cases and thrombospondin type-1 domain containing
7A (THSD7A) autoantibodies present in approximately 2% of cases. Given the strong connection between these
autoantibodies and MN, there is significant movement toward eliminating kidney biopsies in patients showing
serological positivity for autoantibodies against PLA2R and THSD7A. Moreover, serologic tests specific for the
inciting autoantibody (anti-PLA2R or anti-THSD7A) have proven to be highly valued by nephrologists for
monitoring response to therapy and guiding patient care. Reducing the requirement for renal biopsy and
progressing towards a precision medicine approach represent dramatic benefits to patients and the US
healthcare system, alike. For SLE patients at risk for MLN however, predictive autoantigens are only just now
becoming available, with a need for subsequent serological tests. Arkana Laboratories, a leading provider of
histopathological and molecular nephrology diagnostics, evaluated a broad range of MLN biopsy samples in an
effort to identify autoantigens for MLN that may have the same impact as PLA2R and THSD7A have had on non-
lupus MN diagnostics. Using laser capture microdissection, immune complex elution, mass spectrometry, and
bioinformatic proteomic analysis, two proteins, Exostosin 1 and Exostosin 2 (EXT1/2), emerged as candidate
autoantigens for a subset of MLN. Recently published reports from the Mayo Clinic confirm EXT1/2 as likely
autoantigens in MLN. Autoantigenicity was confirmed by staining MLN biopsies for EXT1/2, which exhibited tight
co-localization with IgG in the glomerular membrane. EXT1/2 also co-immunoprecipitated with IgG in extracts
from MLN kidney biopsy tissue. After evaluating over 80 SLE samples, more than 30% were found to be positive
for EXT1/2, with only 1% and 4% exhibiting PLA2R or THSD7A signal, respectively. Interestingly, EXT1/2
circulating autoantibodies have not yet been detected in serological analysis indicating that traditional ELISA-
based assays using recombinant proteins to detect autoantibodies may not support an EXT1/2 diagnostic test
for MLN. This Phase I program will therefore employ phage display biopanning, an unbiased screening method
used to identify high affinity peptide binders, against MLN patient sera and immune complexes from patients with
exostosin-positive MLN that likely contain EXT1/2 autoantibodies. Peptides which bind EXT1/2 autoantibodies
will be further refined to maximize affinity and specificity for future Phase II testing as diagnostic reagents.
项目概要
多达一半的系统性红斑狼疮 (SLE) 患者会发展为狼疮性肾炎 (LN),并且
近三分之一的 LN 患者会出现肾衰竭,需要透析或移植。一种 LN,
与非膜性狼疮性肾炎 (MLN) 相比,膜性狼疮性肾炎 (MLN) 表现出相似的临床特征和损伤模式。
狼疮相关膜性肾病(MN)。 MN 和 MLN 主要通过组织病理学诊断
肾活检分析。此外,已在 MN 中鉴定出自身抗原,即 M 型磷脂酶 A2
受体 (PLA2R) 自身抗体存在于近 70% 的病例中,并且含有血小板反应蛋白 1 型结构域
大约 2% 的病例中存在 7A (THSD7A) 自身抗体。鉴于这些之间的紧密联系
自身抗体和 MN,在消除患者肾活检方面取得了重大进展
PLA2R 和 THSD7A 自身抗体血清学阳性。此外,针对特定人群的血清学检测
事实证明,激发性自身抗体(抗 PLA2R 或抗 THSD7A)受到肾脏病学家的高度重视
监测治疗反应并指导患者护理。减少肾活检的要求
精准医疗方法的进展为患者和美国带来了巨大的好处
医疗保健系统,同样如此。然而,对于有 MLN 风险的 SLE 患者,预测性自身抗原才刚刚出现
变得可用,需要进行后续的血清学测试。 Arkana Laboratories,领先的供应商
组织病理学和分子肾病学诊断,评估了广泛的 MLN 活检样本
努力识别 MLN 的自身抗原,这可能与 PLA2R 和 THSD7A 对非
狼疮 MN 诊断。使用激光捕获显微切割、免疫复合物洗脱、质谱分析和
生物信息蛋白质组分析显示,两种蛋白质,外骨蛋白 1 和外骨蛋白 2 (EXT1/2),成为候选蛋白
MLN 子集的自身抗原。梅奥诊所最近发表的报告证实了 EXT1/2 的可能性
MLN 中存在自身抗原。通过对 MLN 活检组织进行 EXT1/2 染色来证实自身抗原性,该样本表现出紧密的
与肾小球膜中的 IgG 共定位。 EXT1/2 还与提取物中的 IgG 进行免疫共沉淀
来自 MLN 肾活检组织。对 80 多个 SLE 样本进行评估后,发现超过 30% 呈阳性
对于 EXT1/2,分别只有 1% 和 4% 表现出 PLA2R 或 THSD7A 信号。有趣的是,EXT1/2
血清学分析中尚未检测到循环自身抗体,这表明传统的 ELISA-
使用重组蛋白检测自身抗体的检测可能不支持 EXT1/2 诊断测试
对于MLN。因此,该第一阶段计划将采用噬菌体展示生物淘选,这是一种无偏见的筛选方法
用于识别针对 MLN 患者血清和来自患有 MLN 患者的免疫复合物的高亲和力肽结合剂
外骨蛋白阳性 MLN 可能含有 EXT1/2 自身抗体。结合 EXT1/2 自身抗体的肽
将进一步完善,以最大限度地提高未来 II 期测试作为诊断试剂的亲和力和特异性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher P Larsen其他文献
Christopher P Larsen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher P Larsen', 18)}}的其他基金
A proprietary digital platform for precision patient identification and enrollment of clinical trials for rare kidney diseases
用于精确识别患者和注册罕见肾脏疾病临床试验的专有数字平台
- 批准号:
10822581 - 财政年份:2023
- 资助金额:
$ 25.94万 - 项目类别:
Development of a Precision Medicine-based Diagnostic Tool for Membranous Nephropathy
膜性肾病精准医学诊断工具的开发
- 批准号:
10703484 - 财政年份:2021
- 资助金额:
$ 25.94万 - 项目类别:
Rapid Genotyping of ApoL1 Risk Alleles using CRISPR-Cas12a
使用 CRISPR-Cas12a 对 ApoL1 风险等位基因进行快速基因分型
- 批准号:
10384222 - 财政年份:2021
- 资助金额:
$ 25.94万 - 项目类别:
Development of a Precision Medicine-based Diagnostic Tool for Membranous Nephropathy
膜性肾病精准医学诊断工具的开发
- 批准号:
10324016 - 财政年份:2021
- 资助金额:
$ 25.94万 - 项目类别:
Development of a Precision Medicine-based Diagnostic Tool for Membranous Nephropathy
膜性肾病精准医学诊断工具的开发
- 批准号:
10602134 - 财政年份:2021
- 资助金额:
$ 25.94万 - 项目类别:
Development of biomarkers for improved classification of membranous lupus nephritis
开发生物标志物以改进膜性狼疮性肾炎的分类
- 批准号:
9796488 - 财政年份:2019
- 资助金额:
$ 25.94万 - 项目类别:
A Panel-Based Approach to the Diagnosis of Genetic Nephropathies Utilizing Next G
利用 Next G 诊断遗传性肾病的基于面板的方法
- 批准号:
8781824 - 财政年份:2014
- 资助金额:
$ 25.94万 - 项目类别:
相似海外基金
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
- 批准号:
10549640 - 财政年份:2023
- 资助金额:
$ 25.94万 - 项目类别:
Computational modelling and simulation of antibodies to enhance binding affinity of a potential Burkholderia pseudomallei therapeutic
抗体的计算模型和模拟,以增强潜在的鼻疽伯克霍尔德氏菌治疗剂的结合亲和力
- 批准号:
2750554 - 财政年份:2021
- 资助金额:
$ 25.94万 - 项目类别:
Studentship
Affinity Biosensors for COVID-19 Antibodies
适用于 COVID-19 抗体的亲和生物传感器
- 批准号:
61319 - 财政年份:2020
- 资助金额:
$ 25.94万 - 项目类别:
Feasibility Studies
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10013588 - 财政年份:2020
- 资助金额:
$ 25.94万 - 项目类别:
Affinity maturation and property changes of single-domain antibodies through repeated immunizations.
通过重复免疫,单域抗体的亲和力成熟和性质变化。
- 批准号:
20K07009 - 财政年份:2020
- 资助金额:
$ 25.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
基于快速结构的软件可增强抗体亲和力和高通量筛选的可开发性:旨在实现抗体的全面计算机设计
- 批准号:
10603473 - 财政年份:2020
- 资助金额:
$ 25.94万 - 项目类别:
IN SILICO DESIGN OF HIGH-AFFINITY RECOMBINANT ANTIBODIES
高亲和力重组抗体的计算机模拟设计
- 批准号:
2342674 - 财政年份:2020
- 资助金额:
$ 25.94万 - 项目类别:
Studentship
Strategies for generating high affinity antibodies against Gram negative bacteria
产生针对革兰氏阴性菌的高亲和力抗体的策略
- 批准号:
10117194 - 财政年份:2020
- 资助金额:
$ 25.94万 - 项目类别:
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10115604 - 财政年份:2020
- 资助金额:
$ 25.94万 - 项目类别:
Interdisciplinary protein engineering approach to design high affinity antibodies for flaviviruses
跨学科蛋白质工程方法设计黄病毒高亲和力抗体
- 批准号:
10294224 - 财政年份:2018
- 资助金额:
$ 25.94万 - 项目类别: